Study for Topical Antioxidant and Laser Treatment for Acne
This study is looking at how well a topical antioxidant serum (an oil-free vitamin C serum) works with a series of AviClear laser treatments to reduce oily skin and acne. Researchers want to see if this combination can decrease the amount of oil your skin produces. You might be able to join if you are between 18 and 65 years old, have self-perceived "oily skin," and have mild to moderate acne. The study will measure changes in your acne severity and how well you tolerate the treatments. The current recruitment status is unclear.
- Study design
- This is a single-blind study, meaning you won't know which side of your face is receiving which treatment, but the researchers will. It plans to enroll 10 participants.
- What's involved
- You would have visits at baseline (Day 0), Day 14, Day 42, and Day 70. These visits will involve assessments of your skin and questionnaires.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary outcomes are measured at Day 98, suggesting follow-up extends at least until then.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Single-Blind Study Assessing the Use of a Topical Antioxidant With A Series of Laser Procedures to Reduce Sebum Production
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Edward Lain, MD, MBA · PRINCIPAL_INVESTIGATOR · Austin Institute for Clinical Research
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Change in Facial Acne SeverityChange from Baseline at Day 98
Measured by Live Clinical Investigator grading of overall severity of facial acne using the Investigator Global Assessment (IGA). The parameters of the scale are as follows, 0 = clear (best possible outcome), 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe (worst possible outcome). A decrease in scores indicates an improvement in study treatment efficacy. The null hypothesis is that the mean change from baseline is zero.
- Change in Subject TolerabilityChange from Baseline at Day 98
Measured by Live Clinical Investigator grading by subject reporting of burning, stinging, and itching. Each will be measured with the following parameters, 0 = none (best possible outcome), 1 = mild, 2 = moderate, and 3 = severe (worst possible outcome). A decrease in scores or lack of significant increases indicate tolerability of the study treatment. The null hypothesis is that the mean change from baseline is zero.